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Summary 
Human immunodeficiency virus 1 (HW-1) infection is associated with a vigorous cellular immune 
response that allows detection of cytotoxic T lymphocyte (CTL) activity using fleshly isolated 
peripheral blood mononudear cells (PBMC). Although restricting class I antigens and epitopes 
recognized by HIV-l-specific CTL have been defined, the effector cells mediating this vigorous 
response have been characterized less well. Specifically, no studies have addressed the breadth 
and duration of response to a defined epitope. In the present  study, a longitudinal analysis of 
T cell receptor (TCK) gene usage by CTL clones was performed in a seropositive person using 
TCR gene sequences as a means of tracking responses to a well-defined epitope in the glycoprotein 
41 transmembrane protein. 10 CTL clones specific for this human histocompatibility leukocyte 
antigen-B14-restricted epitope were isolated at multiple time points over a 31-mo period. All 
clones were derived from a single asymptomatic HIV-l-infected individual with a vigorous response 
to this epitope that was detectable using unstimulated PBMC. Polymerase chain reaction am- 
plification using Vol and Vfl family-specific primers was performed on each done, followed by 
DNA sequencing of the V-D-J regions. All 10 clones utilized Vo114 and VB4 genes. Sequence 
analysis of the TCK revealed the first nine clones isolated to also be identical at the nudeotide 
level. The TCK-o~junctional region sequence of the tenth done was identical to the junctional 
region sequences of the other nine, but this clone utilized distinct DB and JB gene segments. 
This study provides evidence that the observed high degree of HIV-l-specific CTL activity may 
be due to monodonal or oligoclonal expansion of specific effector cells, and that progeny of 
a particular  CTL clone may persist for prolonged periods in vivo in the presence of a chronic 
productive viral infection. The observed limited TCR diversity against  an immunodominant 
epitope may limit recognition of virus variants with mutations in regions interacting with the 
TCR,  thereby facilitating  immune escape. 
H 
'IV-1 is a retrovirus that causes a persistent productive 
. infection in humans (for a review see reference 1). De- 
spite the progressive and ultimately profound immunosup- 
pression characteristically induced by this virus, infection is 
initially associated with a cellular immune response of un- 
precedented magnitude. The extent of this immune response 
is such that HLA class 1-restricted,  HIV-l-specific CTL ac- 
tivity can be detected in fleshly isolated PBMC from infected 
persons without the need for in vitro stimulation and expan- 
sion that is required to isolate CTL in other viral infections 
(2-7). A potential functional role for these cells as a host de- 
fense is supported by the finding that CD8 + T lymphocytes 
from infected persons, with characteristics of HIV-l-specific 
CTL, can inhibit virus replication in vitro (8-10). These ob- 
servations support  the hypothesis that HIV-l-specific CTL 
play an important role in the course of HIV-1 infection and 
contribute to the prolonged asymptomatic phase typical of 
this disease. 
CTL recognize infected cells through a specific interaction 
involving the TCR and MHC-antigen complex on the target 
cell surface. In general, CTL of the CD8 phenotype recog- 
nize viral peptides of 8-10 amino acids in length that are 
processed endogenously within infected cells and presented 
to  the TCR  as  a  trimolecular complex involving class I 
molecule and fl2-microglobulin  (11-13). CTL of the CD4 
phenotype recognize longer peptides, often 13-17 amino acids 
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lysosomes and presented to the CTL as a complex with a 
class II molecule (14,  15).  The specifidty of CTL for this 
antigen-HLA complex is imparted by the TCR, a hetero- 
dimer consisting of variable a  and B chains (16, 17) that are 
noncovalently associated with five invariant molecules com- 
prising the CD3 complex. In a manner analogous to Ig gene 
rearrangements, TCR diversity is generated by the somatic 
rearrangement of noncontiguous V, D, andJ regions. Diver- 
sity is further increased by the addition of nongermline en- 
coded nucleotides at junctions of these rearranged segments 
(N region diversity). This allows for an enormous potential 
repertoire of >1015 distinct TCR (17). It is the highly vari- 
able CDR3 region that is thought to interact with antigenic 
peptides bound to the MHC cleft, whereas the constant prox- 
imal domains function to secure the TCR complex in the 
cell membrane (18-20). 
Studies of a number of viral infections have attempted to 
define the extent of TCR diversity among CTL clones specific 
for a particular epitope, and thereby address the smacaL,~func- 
tion relationship of the TCR and provide insights into the 
host effector response to infection. The majority of these 
studies have been in inbred murine modal systems and have 
analyzed TCR usage by immune effector  cells at a single point 
in time. These murine studies have often shown limited het- 
erogeneity in Vc~ and VB gene usage among CTL clones 
specific for the same epitope, but V-D-J diversity has usually 
been observed (21-23),  and  similar  results  were recently 
reported in a rhesus monkey infected with simian immunode- 
ficiency virus (SIV) (24).  The study of TCR usage against 
viral epitopes recognized by human CTL has been limited 
and largdy confined to acute viral infections in which the 
immune response is able to effectively  eradicate infection (25, 
26). There have been no studies ofTCR gene usage by virus- 
specific, class I-restricted CTL responses in humans over the 
course of a chronic viral infection. 
The precise characterization of HIV-l-specific CTL re- 
sponses  in infected persons, including the definition of re- 
stricting HLA antigens and optimal CTL epitopes, now offers 
the unique opportunity to study TCR gene usage in a chronic 
human viral infection, and to determine the duration of a 
given effector response by using TCR sequence analysis as 
a means of identifying specific donal responses. In the present 
study, we have examined the TCR  usage by CTL clones 
specific for a dominant nine amino acid epitope in the trans- 
membrane glycoprotein (gp)l  of HIV-1  (gp41/584-592). 
Over a 31-mo period, multiple CTL clones were derived from 
an infected individual by limiting dilution directly from the 
peripheral blood, using a CD3-specific mAb or PHA as a 
stimulus for T  cell  proliferation.  All of the HIV-1  enve- 
lope-specific CTL clones were found to utilize genes from 
the identical Vo~ and V~ TCK gene families. The first nine 
clones  isolated  over  a  27-mo  period  had  identical  TCR 
1  Abbreviations used in this paper: B-LCL, B lymphoblastoid  cell line; gp. 
glycoprotein; LCMV, lymphocytic  choriomeningitis  virus. 
sequences,  even at  the nucleotide level,  indicating an un- 
precedented degree of TCR homology in the response to a 
viral CTL epitope, and providing evidence for a sustained 
clonal effector  response to a CTL epitope in an ongoing chronic 
viral infection. 
Materials and Methods 
Subjects.  Subject 010-115i has been previously shown to have 
significant envelope-specific  CTL activity (27, 28). During the 
period of study from February 1990 to January 1993, this subject 
was asymptomatic with a CD4 § lymphocyte count ranging from 
600 to 800 cells/ram ~. This subject gave written informed con- 
sent and the study was approved  by the Massachusetts  General Hos- 
pital Human Studies Committee. 
Cell Lines.  EBV-transformed B lymphobhstoid cell lines (B- 
LCL) were established and maintained as described previously (2, 
4) in RPMI 1640 medium (Sigma Chemical Co., St. Louis, MO) 
containing 20% (vol/vol) heat-inactivated FCS (Sigma Chemical 
Co.). RPMI 1640, used for all cell lines, was supplemented with 
L-glutamine  (2 raM), penicillin (50 U/m1), streptomycin  (50/ag/ml), 
and Hepes (10 raM). All B-LCL were free of mycoplasma  infection 
by standard culture techniques. 
HLA Typing.  HLA typing was performed by the Massachusetts 
General Hospital Tissue Typing Laboratory using standard sero- 
logical techniques. The complete HLA type of subject 010-115i is 
A2,28; B14,52; Cw8; DR1,2;  DQI. 
Synthetic Peptides.  Synthetic HIV-1 envelope  peptides 25 amino 
acids in length and adjacent peptides that overhpped by eight amino 
acids were synthesized by Multiple Peptide Systems (San Diego, 
CA) according to the PV22 sequence (29), as was peptide RT/648- 
672. Smaller peptides for fine mapping studies were synthesized 
by Cambridge Research  Biochemicals  (W'rlrnington, DE). The nine 
amino acid peptide gp41/584-592 was synthesized as a COOH- 
terminal acid according to the HIV-1 HXB2 sequence. The se- 
quences of peptides containing CTL epitopes in the single letter 
amino acid code described in this study were as follows: gp41/584- 
592: ERYLKDQQL;  RT/648-672:AIYLALQDSGLEVNIVTD- 
SQYALGI. 
1so/at/o~ ofH~I ~/~,~-~/~c CTL C~.  CTL clones  were 
isolated and maintained as described  previously  (27, 28, 30). Briefly, 
PBMC obtained by separation on l~icoll-sodium  diatrizoate (Histo- 
paque 1077; Sigma Chemical Co.) were incubated at 50 or 25 cells 
per well in 96-well plates with 200 ~1 of feeder cell solution con- 
taiuing 106/ml irradiated allogeueic PBMC from HIV-l-seronega- 
tive subjects in RPMI 1640 with 10% heat-inactivated FCS (R10) 
supplemented with 100 U/ml of human rib2 (Hoffman-La  Roche, 
Nutley, NJ). After 2-3 wk, the percentage of wells exhibiting 
growth typically was 40-60% of wells plated at 50 cells/well, and 
15-35% at 25 cells/well (27, 30, 31). As a stimulus to T cell prolifer- 
ation, either the CD3-specific mAb 12F6 (32) was added at 0.1 
/~g/ml or PHA was added at 0.25/~g/ml (Nurex Diagnostics Inc., 
Atlanta, GA). After 2-3 wk, cells  from wells demonstrating growth 
were then transferred to 24-well plates and restimuhted by adding 
I ml of  rlL,2-containing medium with irradiated allogeneic  PBMC 
(10Vml) and anti-CD3  (0.1 #g/ml) or PHA (0.25/~g/ml).  Ap- 
proximatdy 2 wk later, clones  were screened  for CTL activity against 
autolognus targets infected with recombinant vaccinia virus ex- 
pressing the HIV-1 envelope glycoprotein of the BH8 isolate of 
HIV-1 (33). Vaccinia  virus expressing other HIV-1 gene products 
(27) or the Escherichia coli B-galactosidase gene (VSC8) were used 
as controls. Clones exhibiting envelope-specific  CTL activity were 
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irradiated allogeneic PBMC. Selected CTL clones were subcloned 
by limiting dilution at 30, 10, 3, and I cell per well in the presence 
of irradiated feeder cells and PHA. Fine mapping of epitopes rec- 
ognized by these CTL clones was  performed using autologous 
B-LCL incubated with overhpping synthetic HIV-1 peptides as de- 
scribed  (27, 28). 
Cytotaxicit?  Assay.  Target cells consisted of  B-LCL infected with 
vaccinia-HIV-1 expression vectors, vaccinia control, or B-LCL in- 
cubated with 100/zg/ml of the relevant peptide for 60 min during 
SlCr hbeling. Cytolyfic activity was determined in a standard SlCr- 
release assay (34) using U-bottomed microtiter plates containing 
104 targets per well.  Plates were incubated in a humidified incu- 
bator at 37~  for 4 h. All assays were performed in duplicate. Su- 
pernatant fluids were then harvested and counted on a Cobra gamma 
counter (Packard Instrument Co., Inc., Downers Grove, IL), and 
percent lysis was determined from the formula: 100  x  [(experi- 
mental release -  spontaneous release)/(maximum release -  spon- 
taneous release)].  Maximum release was determined by lysis of 
targets in detergent (1% Triton X-100; Sigma Chemical Co.). Spon- 
taneous release was <30% of maximal release for all reported assays. 
Limiting Dilution Assays of Memory CTL.  Precursor frequen- 
des of HIV envelope-specific CTL were estimated by performing 
limiting dilutions on freshly isolated PBMC followed by in vitro 
stimulation with the CD3-specific mAb 12F6 (35).  PBMC were 
cultured at 250-16,000 lymphocytes per well in 24 replicate wells 
of 96-well microtiter phtes. To each well was  added 2.5  x  104 
7-irradiated PBMC from an HIV-I-seronegative donor and 0.1 
/zg/ml of 12F6. Wells were then split and assayed for cytotoxicity 
on SlCr-labded autologous B-LCL infected with a vaccinia gp160 
expression vector, or incubated with synthetic envelope  peptide 
gp41/584-592 as well as control target cells infected with VSC8, 
or without peptide. The fraction of nonresponding wells was the 
number of wells in which SlCr release did not exceed the mean 
plus three standard deviations of the spontaneous release of the 24 
control wells over the number of assayed wells (35, 36). Activated 
cell frequency was estimated by the maximum likelihood method 
(37,  38). 
RNA  Isolation and eDNA Synthesis.  Cells  were grown  for 
14-16 d after restimulation and separated from cell debris by Ficoll 
gradient centrifugation in order to minimize RNA contamination 
from residual  feeder cells. Total RNA was isolated from '~5  x 
106 cells by extraction with RNAzol (Cinna/Biotecx, Laborato- 
ries International Inc., priendswood, TX) as described (39). CTL 
clones isolated at different time Points underwent RNA extraction 
at different times in order to minimize the possibility of cross con- 
tamination.  Total RNA (1/~g) was converted into first strand eDNA 
using an oligo dT primer and avian myeloblastosis  virus reverse 
transcriptase according to the manufacturer's specifications (promega 
Corp., Madison, WI). For specimens that were also analyzed by 
anchored PCR, the C region oligonucleotides 3'Cc~ 599-578 (Table 
1) and 3'C/3 529-510 (Table 2) were used to prime eDNA synthesis. 
PCR Amplification.  PCR was performed with a 5' primer from 
each variable o~ (Table 1) or ~ (Table 2) region and a 3' primer from 
the respective C c~ or/~ region. Each reaction was carried out in 
a total volume of 50/~1 containing 1 U  of Amplitaq, 200/zM of 
each dNTP, 1.5 mM MgCh, and 20 pmol of each primer in buffer 
supplied by the manufacturer (parkin-Elmer Cetus Instruments, 
Norwalk, CT). The PCR conditions consisted of 1 min of  denatu- 
ration at 95~  1 min of annealing at 55~  and 1 rain of exten- 
sion at 72~  for 30 cycles in the case of the TCR. cr chain, and 
25 cycles for the TCR/3 chain. In all experiments, two negative 
controls were included: a reagent control, and an aliquot of the 
dissolved total RNA. The RNA control was included to ensure 
that  amplification products were derived from eDNA  and not 
genomic DNA carried over from the RNA extraction process. In 
all cases, no PCK product was visible in the negative control lanes 
as visualized by ethidium bromide-stained agarose gels or Southern 
blot analysis. 
Anchored PCR was performed by a modification of the proce- 
dure of Loh et al. (40). After total RNA extraction and eDNA 
synthesis,  eDNA was spun through a column (chromaspin 400; 
Clontech Laboratories, Inc., Palo Alto, CA) to remove unused primer 
that can interfere with the subsequent tailing reaction (41). The 
cDNA was then concentrated with a microcon-100 concentrator 
(Amicon, Inc., Beverly, MA) and incubated with 10 #1 5 x  ter- 
minal deoxynucleotidyltransferase (TdT) buffer, 1 mM dGTP, and 
15 U TdT (GIBCO BRL, Gaithersburg, MD) in a total reaction 
volume of 50/zl at 37~  for 30 min. PCK was performed with 
an anchor 5' poly C primer (CUACUACUACUACCCCCCCCC- 
CCCCC) and the original 3' primer that was used to prime eDNA 
synthesis  for 30 cycles. The first five cycles of amplification were 
annealed  at 53~  with subsequent cycles annealed  at 58~  The 
denaturation step was 94~  for I rain, the annealing step was for 
1 min, and the extension was at 72~  for 1 min. PCR products 
were then reamplified with the 5' anchor primer and an internal 
"nested" 3' primer (3'Cc~ 470.447 in the case of the c~ chain and 
3'C~ 491-468 in the case of the/~ chain) for 25 cycles with iden- 
tical conditions to the final 25 cycles of the primary amplification. 
After gel purification, the resulting product was cloned directly 
into the pAMP1 vector using the Cloneamp system (GIBCO BILL) 
(42). This method relies on the incorporation of dUMP residues 
in place ofdTMP into the 5' end of  each amplification primer. After 
amplification,  the PCR products contain the dUMP containing 
sequence at their 5' termini. Treatment with uracil DNA glycosy- 
lase removes uracil residues from the DNA strands  derived from 
the amplification primers. The resulting 3' protruding termini allow 
the fragment to anneal to complementary pAMPl vector ends. This 
system eliminates  the need for restriction endonuclease digestion 
and ligation and improves the efficiency of cloning PCR products 
(42). After transformation of DHSo~ cells, plasmid DNA was se- 
quenced to determine the TCR gene sequences of HIV-l-specific 
CTL. 
Characterization  of  the Amplified  PCR Products.  The PCR prod- 
ucts were size fractionated on a 1% agarose gelafter 25 or 30 cycles 
of PCR. After electrophoresis,  the products were transferred to 
nylon membranes (Micron Separations Inc, Westboro, MA). Specific 
DNA sequences were identified by hybridization with 3zp-labeled 
Ca and C/~ probes at a concentration of 1-5  x  106 cpm/ml in 
a mixture containing 6x SSC, 5x Denhardt's solution, and 0.5% 
SDS. Hybridization was carried out at 65~  overnight. The mem- 
branes were washed using a high stringency protocol consisting 
of sequential  washes with 5 x  SSC, 0.5% SDS at room tempera- 
ture, lx  SSC, 1.0% SDS at 37~  and 0.1% SSC, 1.0% SDS at 
65~  Specific DNA sequences were visualized by autoradiography 
using Kodak XAK-films. 
Sequencing.  PCR products were sequenced directly with Se- 
quenase (United States Biochemical Corp., Cleveland, OH), using 
conditions optimized for direct sequencing of double stranded PCR 
products (43). Double stranded plasmid DNA was sequenced after 
alkaline hydrolysis  (44). 
Results 
Recognition of  a gp41 Epitope by Unstimulated  PBMC.  Prior 
analysis of the HIV-1 envdope-specific CTL response in sub- 
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Variable region primers* 
Table  2.  TCR fl Primers 
Variable region primers* 
Vctl 
Vow2 
Va3 
Vow4 
Va5 
Vot6 
Vot7 
Vt~8 
Vt~9 
VtzlO 
Va11 
Vct12 
V,v13 
Va14 
Vc~15 
Va16 
Vcd7 
Vcd8 
Vod9 
Va20 
Va21 
Vo~22 
Va23 
Va24 
Va25 
Vc~26 
Vo~27 
Vo~28 
Vcz29 
Constant 
5'C~ 
5'Ca 
3'Ca 
3'Cet 
TTGCCCTGAGAGATGCCAGAG  Vfll 
GTGTTCCAGAGGGAGCCATTGCC  vfl2 
GGTGAACAGTCAACAGGGAGA  VB3 
AAGACAGAAAGTCCAGTACCTTGATCCTGC  vfl4 
GGCCCTGAACATTCAGGA  vfl5 
GTCACTTTCTAGCCTGCTGA  vfl5b 
AGGAGCCATTGTCCAGATAAA  vfl6 
GGAGAGAATGTGGAGCAGCATC  V~7 
ATCTCAGTGCTTGTGATAATA  V~8 
AATTCTCCGTGTCCATTCTTTGGA  vfl9 
AGAAAGCAAGGACCAAGTGTT  V~lO 
CAGAAGGTAACTCAAGCGCAGACT  vf111 
TGCTGTGTGAGAGGGAATACAAGTG  vB12 
GATCTCCACCTGTCTTGAATTTAG  Vf113 
CAGAGTCTTTTCCTGAGTGTCCGAG  VB14 
GAGTGGGCTGAGAGCTCAGTCAGTG  Vf115 
GCTTATGAGAACACTGCGT  Vf116 
GCAGCTTCCCTTCCAGCAAT  VB17 
AGAACCTGACTGCCCAGGAA  vf118 
CATCTCCATGGACTCATATGA  Vf119 
GACTATACTAACAGCATGT  Vfl20 
ATGTCAGGCAATGACAAGGGAAGC  VB21 
CAGGAGGTGACACAGATTCC  Vf122 
GATCATCCTGGAGGGAAAGA  Vf123 
GGTCAACAGCTGAATCAGCC  vB24 
TCAGTCCTTGATCGTCCAAG  Constant 
TCTGTTCCTGAGCATGCAGG 
TCTATCTCTGGTTGTCCACG  5'C~ 
TCAAGCCGTGATCCTCCGAG  3'CB 
3'C~ 
re~onprimers* 
9-31  GAACCCTGACCCTGCCGTGTACC 
2~49  TGTACCAGCTGAGAGACTCTAAAT 
599-578  ATCATAAATTCGGGTAGGATCC 
47~447  GAGGAAGGAGCGAGGGAGCACAGG 
All sequences listed 5' to Y. 
* The oligonucleotides for V~2, 3, 5-9, 11, 12, and 17-21 are according 
to Panzara et al. (61).  The oligonucleotides for Va23-29 were derived 
from published sequences (62). 
t The 3'Cot 599-578 and 5'Ccr 9-31 oligonudeotides have been described 
by Choi et al. (63). The numbering for the C region primers corresponds 
to the nucleotide position of the C  region exon (64). 
ject 010-115i showed that fresh unstimulated PBMC were 
able to lyse autologous target cells expressing the HIV-1 enve- 
lope protein (27). In addition, characterization of CTL dories 
obtained by limiting dilution after in vitro stimulation with 
AAGAGAGAGCAAAAGGAAACATTCTTGAAC 
GCTCCAAGGCCACATACGAGCAAGGCGTCG 
AAAATGAAAGAAAAAGGAGATATTCCTGAG 
CTGAGGCCACATATGAGAGTGGATTTGTCA 
CAGAGAAACAAAGGAAACTTCCCTGGTCGA 
TTCCCTAACTATAGCTCTGAGCTG 
GGGTGCGGCAGATGACTCAGGGCTGCCCAA 
ATAAATGAAAGTGTGCCAAGTCGCTTCTCA 
AACGTTCCGATAGATGATTCAGGGATGCCC 
CATTATAAATGAAACAGTTCCAAATCGCTT 
CTTATTCAGAAAGCAGAAATAATCAATGAG 
TCCACAGAGAAGGGAGATCTTTCCTCTGAG 
CTGAGATGTCACCAGACTGAGAACCACCGC 
CAAGGAGAAGTCCCCAAT 
GTGACTGATAAGGGAGATGTTCCTGAAGGG 
GATATAAACAAAGGAGAGATCTCTGATGGA 
CATGATAATCTTTATCGACGTGTTATGGGA 
GCACAAGAAGCGATTCTCATCTCAATGCCC 
CATCTGTCTTCTGGGGGCAGGTCTCTCAAA 
ATAGCTGAAGGGTACAGCGTCTCTCGGGAG 
TCTAATATTCATCAATGGCCAGCGACCCT 
GCAGTAGACGATTCACAGTT 
ATGCAGAGCGATAAAGGAAG 
ATCTCAGAGAAGTCTGAAAT 
GATTTTAACAATGAAGCAGA 
region primers* 
26-49  CCGAGGTCGCTGTGTTTGAGCCAT 
529-51o  AATCCTTTCTCTTGACCATG 
491-468  CTGACCAGCACIGCATACAIGGTG 
* The oligonucleotides V/31-11,  and V/313-17 have been described  by 
Wucherpfennig et al. (65). The oligonucleotides V~21-24 were derived 
from published sequences (66,  67). 
t The numbering for the C region primers correspond to nucleotide po- 
sition of the C region exon (68). Primer YCfl 491-468 has inosine residues 
to allow amplification of Cfll and Cfl2 sequences. 
a CD3-specific mAb indicated that a nine amino acid epitope 
in the transmembrane protein gp41 (gp41/584-592) was the 
target recognized by these CTL clones (28). Recognition of 
this nonamer occurs at concentrations as low as I ng/ml (data 
not  shown).  To determine the relative magnitude of the 
envelope-spedfic response directed at this gp41 epitope, un- 
stimulated PBMC from subject 010-115i were tested directly 
for recognition of autologous target cells sensitized with this 
epitope. PBMC were isolated after Ficoll-sodium diatrizoate 
separation and incubated either with vaccinia-infected autol- 
ogous B-LCL expressing gp160, or incubated with HIV-1 
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stimulated PBMC was as high as 53%  at an E/T ratio of 
100:1 (Fig.  1). The magnitude of the response to the gp41 
epitope was similar to that observed with the vacdn~--expressed 
gp160, suggesting that this epitope was the dominant target 
of the activated envelope-specific CTL response in this person. 
Precursor Frequency Analysis of  gp41/584-592-specific CTL, 
To further quantify the CTL response directed at the gp41 
epitope, a formal precursor frequency analysis was performed 
as described (35). Varying concentrations of cells were stimu- 
lated in vitro with a CD3-specific mAb as a polyclonal stimulus 
for T cell proliferation,  and tested for lysis of autologous B-LCL 
either infected with the recombinant vaceinia-HIV-1 enve- 
lope vector or sensitized with HIV-1 peptides. As shown in 
Fig.  2, both envelope-expressing B-LCL as well as B-LCL 
sensitized  with  peptide  gp41/584-592  were  recognized, 
whereas the control target cells were not. The single hit Poisson 
model was fulfilled for all assays as demonstrated by the X  2 
value for goodness of fit (45). The calculated precursor fre- 
quency of CTL directed at the gp41 peptide was 1/1016 (95% 
confidence interval 1/678-1/1,523).  This value was consis- 
tent  with  the  value  of 1/2,041  (95%  confidence interval 
1/1,290-1/3,229) obtained using the vac~nia vector expressing 
the entire envelope protein, indicating that gp41/584-592 is 
the dominant if not the only detectable envelope CTL epi- 
tope recognized by this individual using target cells expressing 
the HIV-1  IIIB strain  of HIV-1. 
Isolation of Envelope-specific CTL Clones.  Having demon- 
strated a dominant CTL response to a single epitope in gp41 
using both unstimulated PBMC and CTL clones, we wished 
to determine the TCR repertoire as well as the longevity of 
effector cells specific for this epitope. Limiting dilution doping 
was performed at multiple time points over a 31-mo period 
using a CD3-specific mAb or PHA as a polyclonal stimulus 
to proliferation, and clones were screened for recognition of 
vaccinia-expressed envelope protein. During this period,  10 
CTL activity of unstimulated PBMC 
60  / 
￿9  ~  4o 
n  .~  30 
~  2o 
~:  10 
0  /"  ,  , 
Vaccinia  Vaccinia-  B-LCL  B-LCL- 
control  gp160  gp41/584-592 
Figure 1.  Lysis  ofautologous B-I.CL infected  with vaccinia o~pressing 
gp160 or incubated with peptide gp41/584-592. Fresh PBMC from sub- 
ject 010-115i were isolated over a Ficoil gradient and incubated with 104 
target cells at E/T ratios of 100:1 and 50:1. Target cells were B-I.CL in- 
fected with a control vaccinia virus, a vaccinia-gp160  vector, or incubated 
with peptide gp41/584-592 or no peptide. Lysis  of target cells incubated 
with irrelevant peptide was always <5%. 
HLA class I-restricted,  envelope-specific CTL clones were 
analyzed, all of which were shown to be HLA-B14 restricted 
and all of which were specific for the epitope gp41/584-592 
(Table 3). Results were similar whether PHA or anti-CD3 
were used as the stimulus for T cell proliferation, indicating 
that the results were not dependent upon the method of poly- 
donal stimulation. Despite screening more than 1,000 clones 
over the period of this study, no clones with specificities  for 
other envelope epitopes were identified.  The percentage of 
screened clones that were specific for this epitope was 0.5-1% 
(data not shown). As the limiting dilution cloning of HIV- 
1-specific CTL from this patient has been reproducible using 
10-25 PBMC per well,  this would correspond to a calcu- 
lated frequency of gp41-specific CTL clones of ~0.1%  of 
seeded PBMC, which is similar to the value derived from 
formal precursor frequency analysis.  These data again indi- 
cate that the envelope-specific response in this person is nar- 
rowly directed, and that the gp41 epitope remains the major 
detectable target for the envelope-specific CTL response in 
this patient. 
CTL Clones Specific for gp41/584-592  in Subject 010-115i 
Utilize TCR Vc~14 and V/34 Genes.  Envelope-specific CTL 
clones recognizing gp41/584-592 were isolated from PBMC 
obtained in February of 1990, August and September of 1991, 
and April and September of 1992. To further ensure donality, 
representative clones from different time points were subdoned 
at limiting dilution. RNA was extracted from active clones, 
and reverse transcription  was performed using an oligo dT 
primer.  TCR gene utilization  was determined by PCR of 
cDNA using specific TCR gene V region primers followed 
1 
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~  0.1 
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Figure 2.  Quantitation  of  envelope  spedfic  CTL. Limiting dilution anal- 
ysis was performed on freshly isolated PBMC from HIV-l-infected  sub- 
ject 010-115i. Targets were ([~) autologous B-LCL infected with control 
vaccinia (VSCS), (ll) autologous B-LCL  infected  with gp160-expressing 
vaccinia (VPE16), (O) autologous  B-LCL  alone, or (0) autologous  B-LCL 
incubated with peptide gp41/584-192. Regression lines were calculated 
by the method of  maximum likelihood  (37, 38). Data are shown for PBMC 
obtained in January 1993. A similar precursor frequency of CTL specific 
for gp41/584-592 was obtained using cryopreserved  ceils from September 
1991 (data not shown). 
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Percent  HIV-1 specific lysis* 
Isolation  HLA B14  HLA B14 
Clone  date  Autologous  match  mismatch  Epitope specificity  TCR Vex  TCR V~ 
115  H10*  2/90  53  53  0  gp 41/584-592  Vex14  V~4 
115  N10*  2/90  50  17  0  gp 41/584-592  Vcd4  VB4 
115 J7*  2/90  53  51  0  gp 41/584-592  Vex14  Vfl4 
115  G1  8/91  88  85  1  gp 41/584-592  Vex14  VB4 
115  I26  9/91  94  99  9  gp 41/584-592  Vex14  VB4 
115  K4  9/91  99  99  12  gp 41/584-592  Vex14  VB4 
115  M19  9/91  99  99  9  gp 41/584-592  Vex14  VB4 
115  M21  9/91  99  99  9  gp 41/584-592  Vex14  V/~4 
115  A7  5/92  76  52  0  gp 41/584-592  Vc~14  V/~4 
115 E15  9/92  64  64  2  gp 41/584-592  Vo~14  VB4 
115 D7  5/92  85  74  1  RT/648-672  Vo121  VB14 
* Target cells consist of B-LCL incubated with  synthetic peptide. E/T ratios are 10:1. Spontaneous lysis of target cells was always <30%. 
* The epitope specificity and HLA restriction of clones 115 H10,  115 N10,  and 115 J7 have been previously reported (28). 
by Southern blot and hybridization with radiolabded probe. 
In all cases, a single dominant Vot and VB band was visual- 
ized by ethidium  bromide-stained gels and Southern blot anal- 
ysis. A representative  Southern blot is shown in Fig. 3. All 
envelope-specific CTL analyzed from this patient utilize the 
Voe14 and VB4 TCP, genes (Table 3). 
To further assess the similarity among the envelope-specific 
clones, the r  and ~ TCR genes were sequenced.  PCR am- 
plified products were isolated and sequenced directly in order 
to minimize the effects of Taq-generated  errors.  The TCR 
Vcx-Jcx and VB-Dfl-JB sequences of the first nine dones iso- 
lated were identical at the nudeotide level, suggesting that 
these clones, which were obtained over a 27-mo period, were 
all progeny of a single progenitor clone (Fig. 4). The TCR 
Vcx-Jcz region sequence of a clone isolated at the final time 
point, 115 E15, was also identical to the nine clones previ- 
ously isolated.  Although this clone shared Vcd4 and VB4 
gene usage with the other clones, sequencing of the B chain 
revealed distinct D~ and J3 gene segments. To confirm iden- 
tical Vot-Jcx usage and distinct D~-J~ usage by done 115 E15, 
additional studies were performed, eDNA from both the 
parent clone and a subclone was subjected to PCR amplifi- 
cation using the Vex14 primer, followed by direct sequencing. 
RNA was extracted from the clone and subdone at separate 
times, and eDNA synthesis was performed separately as well. 
PCP, amplifications of the different eDNA preparations were 
not performed concurrently with previously isohted envelope- 
specific CTL clones. Results were identical for both clones, 
confirming the presence of Vo~14-Jcx sequences identical to 
the nine clones previously isolated.  As in all other experi- 
Figt~ 3.  IklazsentativeSoutlm~ 
blot  of  a  gp41/584-592-specitic 
CTL  clone using family-specific 
primers for the Vo~ and V~ regions. 
The PCR products generated  from 
clone 115M21 were separated on a 
1% agarose gel and blotted onto 
nylon membranes. Southern blot 
analysis was  performed with  a 
random hbeled C region fragment. 
(W)  Reagent control,  (R) RNA 
control. (A) Vcd-29, probed with 
C~x  fragment  generated  from 
primers 5'Cot 26-49 and 3~  470- 
477. Positive control is Cox region amplified with 5'Cr  9-31 and 3'Cr  599-578 primers. The faint lower molecular weight band seen in lane V~x13 
was sequenced  and found to be a fragment of C region DNA without a V,v13 sequence. (/3) VB1-24, probed with CB fragment generated from primers 
5'C3 26-49 and 3'CB 491-468. Positive control is CB region amplified with  5'CB 26-49 and 3'CB 529-510 primers. 
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115  MI9  .............................................................................. 
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VEDWGGAT  SYNE0VVGPOTRLTVLj~2.1 
115  El5  ...............  ggggaAsa.g.~g  gocg.g4g~l.gg~,.gg  tee  tac  aat  gag  cag  tte  ttc  gCg  eta  ggg  aca  cog  ere  acc  geg  eta  ......... 
(A) TCR sequences of Vow-Jot region of CTL clones from subject 010-115i. The nomenclature of the Jr, segment is according to Moss  Figure 4. 
et al. (69). (B) TCR V~-DB-J~ sequences of CTL clones from subject 010-115i. Non germline insertions of ,~ and B TCR sequences are underlined. 
These sequence data are available from EMBL/Genbank/DDBJ under accession numbers Z29579, Z29580, Z29581, Z29582, and Z29614. 
ments, reagent controls were negative, indicating that tem- 
plate contamination of the Vc~14 primer had not occurred. 
In addition, attempts to amplify cDNA from clones isolated 
from other individuals with the Vod4 primer were unsuc- 
cessful, again ruling out contamination of reagents. 
Further analysis of Vc~ and VB usage by clone 115 E15 
was also undertaken. Anchored PCR and sequencing of a 
subdone of 115 E15, as well as a subclone of a representative 
clone from an earlier time point,  115 M21, was performed 
in order to determine whether Vc~14 and VB4 usage by these 
clones might represent different subfamilies. Results revealed 
the use of identical VB4 genes. Each subclone had only one 
TCR B chain rearrangement and the sequences of the DB 
and JB regions were identical to those derived from direct 
sequencing using the family-specific V~4 primer. Anchored 
PCR of the ot sequences of these two clones confirmed the 
Vc~-Jc~ sequences derived using the family-specific primers. 
However, different subfamilies of  Vod4 were utilized by each 
clone, Vc~14.2 in the case of CTL clone 115 M21 and Va14.1 
in the case of CTL clone 115 E15 (data not shown). 
Sequence comparison  between the D  region of 115 E15 
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and the previously isolated clones reveal four shared amino 
acid residues (Fig. 4). In addition,  this clone from the Sep- 
tember 1992 time point utilizes the J/J 2.1 gene instead of 
theJB 1.2 gene common to the other nine clones. These data 
suggest that the earlier CTL response to the dominant gp41 
epitope was mediated predominantly by donal expansion of 
a single effector cell popuhtion that persisted over a prolonged 
period of time in the setting of a persistent infection.  The 
finding of a distinct clone with identical epitope specificity 
at a later time point with an identical TCR V~-Jc~ sequence 
and shared VB4 usage implies sdection for certain TCR de- 
ments in the envelope-specific response of this patient. 
Vc~14 and V~4 Usage Is Not a Feature of all HLA-BI4- 
restricted Clones.  Although the use of Vod4 and V~4 was 
a common feature of  all HLA-B14-restricted envelope-specific 
CTL clones from subject 010-115i, the use of these genes was 
not a feature of other HLA-B14-restricted  clones. An HLA- 
B14-restricted CTL done from this subject that was specific 
for a reverse transcriptase (RT) epitope utilized the Vc~21 and 
VB14 genes (Table 3). In addition,  preliminary data gener- 
ated from a CTL done from a second subject that is also specific for the gp41/584-592 epitope and restricted by HLA- 
B14 indicates that the TCR utilizes the Vex22 and Vfll genes 
(data not shown). These data indicate that structural con- 
straints  imposed by the HLA-B14 molecule or the HLA- 
B14-peptide complex do not limit recognition to CTL ex- 
pressing Vex14 and Vfl4 genes. 
Discussion 
In this study we have investigated the CTL response to 
a defined immunodominant  HW-1 epitope, using TCR anal- 
),sis as a means of identifying and following donal CTL re- 
sponses. To characterize the breadth and duration of a response 
that was of sufficient magnitude to be detected using freshly 
isolated PBMC, this study was performed on an asymptom- 
atic seropositive person with a vigorous CTL response to a 
nine amino acid epitope in the transmembrane protein gp41. 
This HIV-1 epitope is contained in a region that has been 
shown to be a target for both class I (28, 46)- and class II-re- 
stricted CTL (47), and also contains a major B cell epitope 
(48). Two different methods were used to obtain clones in 
order to protect against possible selection bias. Both anti- 
CD3 mAb and PHA as stimuli for T cell proliferation yielded 
clones directed against this epitope. The high frequency with 
which these clones were obtained by limiting dilution was 
similar to the calculated frequency of these cells in bulk PBMC, 
providing supportive evidence that these clones are reflective 
of the ~'uhting CTL population. Our data indicate a striking 
homogeneity in this response in that all clones isolated over 
the first 27 mo of study utilized Vc~14 and V~4 genes, and 
were sequence identical This indicates  that the detectable 
response during the initial period of study was mediated by 
a donal expansion of a single progenitor cell. A single gp41- 
specific done isolated at the 31-mo time point also utilized 
Vc~14 and V/34, with an identical Vc~-J~ sequence, but with 
sequence changes occurring in the D-J segments of the/3 
chain, suggesting structural constraints on epitope recognition. 
The analysis of CTL in animal models of viral infections 
has shown limited TCR heterogeneity among CTL specific 
for defined epitopes, but the degree of homogeneity  observed 
in our study, as well as the durability of the response,  has 
not been previously reported. Each of the previous studies 
has had important distinctions compared with our study. In 
the murine lymphocytic choriomeningitis virus (LCMV) 
model, recognition of a dominant H-2Db-restricted enve- 
lope epitope, GP-2, was shown to be mediated by CTL that 
utilized the Va4 and V/310 gene segments. Southern blot 
analysis indicated that each done had a distinct TCR rear- 
rangement. However, in that study, the DNA sequencing 
was performed on a single done so the degree of similarity 
between the D  and J regions of the o~ and fl chains could 
not be determined (21). Another study analyzed CTL clones 
spedfic for this same epitope and although four of four clones 
utilized Vol4, three different Vfl genes were utilized. No pat- 
terns were evident in the Vo~-Jo~ regions or the Vfl-Dfl-Jfl 
regions in these clones (22). The restricted V gene usage was 
not dependent on MHC restriction in this system as CTL 
clones specific for an H-2Db-restricted GP-1 epitope did not 
share Vc~4 gene segment usage (23). In a primate model of 
SIV infection, Chen et al. (24) have described limited TCR 
Vfl andJB gene usage by SIV gag-sp~'ific CTL. In that study, 
six CTL clones with identical epitope spedficity and MHC 
class I restriction were isolated at a single time point from 
a single monkey. Five out of six of these clones utilized the 
Vf123 gene segment and four out of six utilized the JB 1.2 
gene segment. Two pairs of clones differed in the DB region 
by only one amino acid but despite this similarity, all o~ and 
/3 chains were distinct, indicating a polyclonal response to 
this epitope. This response was analyzed at only a single point 
in time, therefore this study could not determine whether 
this pattern of TCR gene usage remained stable over the course 
of the disease. 
The analysis of TCR gene usage by human virus-specific 
class I-restricted CTL to date has been limited to influenza 
virus infection. In a study of HLA-A2-restricted CTL specific 
for an influenza matrix epitope, PBMC were stimulated with 
influenza virus and antigenic peptide and subcloned on an- 
tologous B-LCL pulsed with antigenic peptide (25).  That 
study demonstrated shared Vex10 and Vf117 gene usage among 
three CTL lines from two subjects.  Two of the influenza- 
specific CTL lines from one patient had identical TCR c~ 
chains at the nucleotide level and shared V/3 gene usage, yet 
had distinct D/3 andJfl gene segments, similar to our finding 
of an invariant TCR Va-JoL sequence  among gp41/584- 
592-specific CTL clones from subject 010-115i. This pheno- 
menon of invariant a  or/3 TCR chain usage has also previ- 
ously been described in murine T cell dones specific for 2,4,6- 
TNP (49),  pigeon cytochrome c (50),  Ig )~2 L chain (51), 
)x repressor  (52),  and myoglobin peptides (53).  Conserved 
TCR gene usage among HLA-B27-restricted influenza A 
virus-specific CTL clones has recently been described as well 
(26). Whereas the findings of limited TCR usage by a CTL 
response in an individual were similar, the protocols for the 
generation of CTL were different. We cloned T cells directly 
from peripheral blood and did not rely on in vitro stimula- 
tion with viral antigen in hopes of obtaining a more repre- 
sentative  sample of circulating CTL. We also avoided the 
potential problem of generating primary in vitro CTL re- 
sponses (54). Because of the chronic nature of HIV-1 infec- 
tion, we were able to follow this TCR usage over an ex- 
tended period of time and we provide evidence that in certain 
instances the high level of CTL activity may be due to donal 
expansions of specific CTL. 
In addition to demonstrating a homogeneous response to 
a viral CTL epitope, our study also provides important in- 
formation regarding the duration of a specific clonal CTL 
response. The persistence of activated HIV-l-specific human 
CTL has not previously been evaluated.  A previous study 
assessing the longevity of virus-speci]ic CTL has involved the 
adoptive transfer of LCMV-specific CTL in the murine model. 
In these studies it was shown that donor CD8 + CTL could 
be recovered up to 9 mo after transfer and still maintain their 
activity against LCMV in vitro and in vivo (55). These CTL 
persist despite the absence of antigen in the recipient mice. 
Our study has allowed us to evaluate the persistence of CTL 
in a chronic viral infection. The ability of bulk PBMC to 
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ongoing in vivo activation  of these CTL. 
The homogeneous TCR response to an immunodominant 
epitope may be significant for a number of reasons.  It has 
been suggested that clonal expansion followed by clonal ex- 
haustion due to the continuous stimulation of effector cells 
may be involved in the diminution of specific CTL responses, 
as recently demonstrated in a routine model of persistent viral 
infection (56). Our data provide support for the hypothesis 
that continuous in vivo stimulation by a chronic viral infec- 
tion can result in donal expansion of effector cdl~ Continued 
longitudinal study of the TCR repertoire of HIV-l-specilic 
CTL will aUow us to address the ultimate fate of these cells. 
Limited aloha1 responses to dominant epitopes may also fadli- 
tate immune escape, which has been postulated to play a role 
in disease pathogenesis (57). The homogeneous TCR response 
directed against this immunodominant  epitope may imply 
that antigenic variation in this region of the virus can more 
readily lead to escape from immune recognition. Escape from 
a homogeneous CTL response has been described in LCMV- 
infected mice transgenic for a single TCR (58), and a later 
study showed that LCMV-specific CTL clones can select for 
escape mutants in vitro (59).  Two of the envelope-specific 
CTL described in this report have been evaluated for their 
ability to recognize peptides with amino acid substitutions 
representing those found in naturally occurring HIV-1 iso- 
lates. Several of these substitutions resulted in partial to com- 
plete loss of recognition of this epitope (27). It has also been 
shown that T  cells with distinct TCR, all of which recog- 
nize the same epitope, can differ in their fine specificity to- 
ward amino add substitutions (60). It is possible that a broader 
TCR repertoire for specific epitopes may allow for continued 
recognition of virus by a subpopulation of CTL despite mu- 
tations in CTL epitopes. Studies are in progress to analyze 
HIV-1 sequence variation in areas of CTL epitopes to ad- 
dress the issue of immune escape from CTL recognition. 
In summary,  this study provides evidence of a persistent 
clonal response to a CTL epitope in a chronic viral infection 
and indicates that the vigorous effector response is mediated 
by an extremely restricted TCR repertoire. Expanded studies 
should facilitate the analysis of structural constraints on epi- 
tope  recognition  and,  by  tracking  TCR  usage  by HIV- 
1-specific CTL, help to determine whether clonal CTL dele- 
tion is a factor in disease pathogenesis. 
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